FDA approves weight loss drug Zepbound to treat obstructive sleep apnea - KPBS
Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. The drug, used with a reduced-calorie diet and exercise, aids weight loss and reduces OSA symptoms. Studies showed significant reductions in shallow breathing or pauses in breathing among Zepbound users compared to placebo.
Highlighted Terms
Related News
Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. The drug, used with a reduced-calorie diet and exercise, aids weight loss and reduces OSA symptoms. Studies showed significant reductions in shallow breathing or pauses in breathing among Zepbound users compared to placebo.